4 research outputs found

    Validation de la détermination de l'insulinémie chez le chien par deux méthodes ELISA

    No full text
    Le diabète sucré est une des dysendocrinies les plus fréquentes chez le chien. La détermination de l'insulinémie dans cette espèce est peu réalisée en pratique, alors que ce dosage présente un intérêt majeur dans le typage et le suivi du diabète sucré ainsi que dans le diagnostic d'insulinome. Le but de cette étude a été d'évaluer deux kits ELISA (Enzyme-linked immunosorbent assay) pour la détermination de l'insulinémie chez le chien, un kit homologue spécifique du chien (Mercodia) et un kit hétérologue (Dako) (dosage de l'insuline plasmatique chez l'homme). Le dosage a été réalisé respectivement sur 71 et 41 chiens en bonne santé et à jeun et a permis la validation de ces deux méthodes de dosage ainsi que l'établissement d'intervalles de valeurs usuelles de l'insulinémie dans l'espèce canine : [2.7 ; 58.56 pmol/L] et [62.17 ; 742.5 pmol/L] respectivement pour le kit Mercodia et le kit Dako.TOULOUSE-EN Vétérinaire (315552301) / SudocTOULOUSE3-BU Santé-Centrale (315552105) / SudocSudocFranceF

    Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study

    No full text
    Introduction: The BNT162b2 mRNA-based vaccine has shown high efficacy in preventing COVID-19 infection but there are limited data on the types and persistence of the humoral and T cell responses to such a vaccine. Methods: Here, we dissect the vaccine-induced humoral and cellular responses in a cohort of six healthy recipients of two doses of this vaccine. Results and discussion: Overall, there was heterogeneity in the spike-specific humoral and cellular responses among vaccinated individuals. Interestingly, we demonstrated that anti-spike antibody levels detected by a novel simple automated assay (Jess) were strongly correlated (r=0.863, P<0.0001) with neutralizing activity; thus, providing a potential surrogate for neutralizing cell-based assays. The spike-specific T cell response was measured with a newly modified T-spot assay in which the high-homology peptide-sequences cross-reactive with other coronaviruses were removed. This response was induced in 4/6 participants after the first dose, and all six participants after the second dose, and remained detectable in 4/6 participants five months post-vaccination. We have also shown for the first time, that BNT162b2 vaccine enhanced T cell responses also against known human common viruses. In addition, we demonstrated the efficacy of a rapid ex-vivo T cell expansion protocol for spike-specific T cell expansion to be potentially used for adoptive-cell therapy in severe COVID-19, immunocompromised individuals, and other high-risk groups. There was a 9 to 13.7-fold increase in the number of expanded T cells with a significant increase of anti-spike specific response showing higher frequencies of both activation and cytotoxic markers. Interestingly, effector memory T cells were dominant in all four participants’ CD8+ expanded memory T cells; CD4+ T cells were dominated by effector memory in 2/4 participants and by central memory in the remaining two participants. Moreover, we found that high frequencies of CD4+ terminally differentiated memory T cells were associated with a greater reduction of spike-specific activated CD4+ T cells. Finally, we showed that participants who had a CD4+ central memory T cell dominance expressed a high CD69 activation marker in the CD4+ activated T cells.This research was funded by Academic Health System, Medical Research Center, Hamad Medical Corporation, Doha, Qatar, grant number MRC-01-21-113, and the Article Processing Charges was funded by Academic Health System, Medical Research Center, Hamad Medical Corporation, Doha, Qatar. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication
    corecore